324 related articles for article (PubMed ID: 7112499)
1. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
[TBL] [Abstract][Full Text] [Related]
2. Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs.
Thomas DP; Merton RE; Barrowcliffe TW
Ann N Y Acad Sci; 1989; 556():313-22. PubMed ID: 2735662
[TBL] [Abstract][Full Text] [Related]
3. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
4. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antithrombotic activity of two heparin fragments PK 10169 (mol. wt. 5,000) and EMT 680 (mol. wt. 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: relative importance of systemic anti-Xa and anti-IIa activities.
Bara L; Trillou M; Mardiguian J; Samama M
Nouv Rev Fr Hematol (1978); 1986; 28(6):355-8. PubMed ID: 3562219
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
[TBL] [Abstract][Full Text] [Related]
7. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
8. Studies in man and experimental animals of a low molecular weight heparin fraction.
Thomas DP; Merton RE; Lewis WE; Barrowcliffe TW
Thromb Haemost; 1981 Jun; 45(3):214-8. PubMed ID: 7281101
[TBL] [Abstract][Full Text] [Related]
9. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.
Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA
Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500
[TBL] [Abstract][Full Text] [Related]
10. Effect of continuous low-dose intravenous heparin administered during operation on postoperative measurements of antithrombin III and antifactor Xa.
Jennings SA; Heather BP; Greenhalgh RM
Surgery; 1984 Sep; 96(3):550-5. PubMed ID: 6474360
[TBL] [Abstract][Full Text] [Related]
11. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions.
Hoppensteadt DA; Walenga JM; Fareed J
Semin Thromb Hemost; 1985 Apr; 11(2):112-20. PubMed ID: 3898369
[TBL] [Abstract][Full Text] [Related]
12. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D
Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482
[TBL] [Abstract][Full Text] [Related]
13. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model.
Thomas DP; Merton RE; Gray E; Barrowcliffe TW
Thromb Haemost; 1989 Apr; 61(2):204-7. PubMed ID: 2546282
[TBL] [Abstract][Full Text] [Related]
14. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
Diness V; Ostergaard PB
Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
[TBL] [Abstract][Full Text] [Related]
15. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
16. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
[TBL] [Abstract][Full Text] [Related]
17. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats.
Hobbelen PM; van Dinther TG; Vogel GM; van Boeckel CA; Moelker HC; Meuleman DG
Thromb Haemost; 1990 Apr; 63(2):265-70. PubMed ID: 2363127
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
Walenga JM; Petitou M; Lormeau JC; Samama M; Fareed J; Choay J
Thromb Res; 1987 Apr; 46(2):187-98. PubMed ID: 3603420
[TBL] [Abstract][Full Text] [Related]
20. The monitoring of heparin administration by screening tests in experimental dogs.
Mischke R; Jacobs C
Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
